(Q34498450)

2 August 2017

title

Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors (English)

1 reference

Hepatic artery embolization

2 August 2017

main subject

1 reference

1 reference

Jonathan R Strosberg

1

1 reference

2 August 2017

Junsung Choi

series ordinal

2

1 reference

2 August 2017

Alan B Cantor

series ordinal

3

1 reference

2 August 2017

Larry K Kvols

series ordinal

4

1 reference

2 August 2017

publication date

1 January 2006

1 reference

2 August 2017

1 reference

2 August 2017

volume

13

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

72-78

1 reference

Karnofsky memorial lecture. An odyssey in the land of small tumors.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Ablative therapies for liver metastases of digestive endocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Management of neuroendocrine liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Treatment of the carcinoid tumor and the malignant carcinoid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin--alone or in combination with 5-FU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

The management of patients with advanced carcinoid tumors and islet cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Control of carcinoid syndrome with hepatic artery embolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480601300110

10.1177/107327480601300110

21 January 2018

Identifiers

DOI

0 references

1 reference